ABIVAX Société Anonyme (ENXTPA:ABVX) Following New Leadership Hires And Wider Losses Looks Undervalued
ABIVAX Société Anonyme (ENXTPA:ABVX) has tightened the focus on late stage execution after reporting wider first half losses and heavier cash use, installing a new Chief Medical Officer and Chief Technical Officer alongside extended funding.
The recent leadership appointments and deeper first half losses come alongside a share price that has slipped, with a 30 day share price return of 15.91% and a 90 day share price return of 29.09%. Yet ABIVAX Société Anonyme still carries a 1 year total shareholder return of 15.51% and a very large 3 year total shareholder return, signalling that long term holders have seen strong gains while short term momentum has faded as investors reassess execution risk and funding needs around obefazimod.
Scan how ABIVAX Société Anonyme compares with other late stage, higher risk biotech stories by reviewing the curated 226 resilient stocks with low risk scores that still aim to keep downside in check.
ABIVAX Société Anonyme trades at a steep 65% discount to the average analyst target, even after the recent pullback and heavier losses. Is that caution a warning sign or a valuation gap?
Most Popular Narrative: 63% Undervalued
On the most followed valuation storyline, ABIVAX Société Anonyme is framed with a fair value of €220 per share against a last close of €81.9, which casts the current pullback in a very different light.
In my opinion, Abivax is worth much more than its current share price of around €136. The market still seems to value the company as if there is a lot of uncertainty, but I believe much of that uncertainty has now been reduced. The company's lead drug, obefazimod, has delivered strong Phase 3 results in ulcerative colitis, and recent safety updates have helped rebuild investor confidence. At the same time, Abivax has raised enough cash to fund its operations for several years, meaning it can focus on getting the drug approved and launched instead of worrying about raising more money.
See why 7 investors see ABIVAX Société Anonyme as 63% undervalued.
Result: Fair Value of €220 (UNDERVALUED)
Still, the story around ABIVAX Société Anonyme can unravel quickly if obefazimod stumbles in late stage development or if future funding terms dilute existing shareholders.
Find out about the key risks to this ABIVAX Société Anonyme narrative.
Another View: Market Ratios Push Back On The ABIVAX Société Anonyme Story
While the popular narrative tags ABIVAX Société Anonyme as deeply undervalued, the market ratio picture is less generous. The stock trades on a P/B of 19.5x, compared with 2.7x for the French biotech sector and 36.6x for peers. This signals rich pricing against the broader industry, even if it screens cheaper within its immediate peer group. For anyone weighing that €220 fair value pitch, the question is whether paying such a premium to sector book values leaves enough room for error.
See what the numbers say about this price in our valuation breakdown See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Sentiment around ABIVAX Société Anonyme is clearly split, which is exactly why it pays to move quickly and test the story against the underlying data yourself rather than lean on headlines or a single valuation model. To see the mix of concern and optimism in one place, start with the 1 key reward and 2 important warning signs.
Looking for more investment ideas beyond ABIVAX Société Anonyme?
Do not stop your research with a single biotech story. Broaden your watchlist with a few carefully filtered sets of stocks that match different goals.
- Target financially solid contenders and stress test your downside risk profile with the list of solid balance sheet and fundamentals (201 results).
- Hunt for mispriced opportunities by scanning the 186 high quality undervalued stocks that combine quality fundamentals with more attractive entry points.
- Build a cash flow focused watchlist and zero in on income ideas using the 159 dividend fortresses.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com